Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C421
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Chronic myeloid leukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification. In most cases, NOS histology is only the provisional diagnosis; the physician will run further diagnostic procedures and look for various clinical presentations to identify a more specific disease. Further review of the medical record should be done to look for the tests listed as definitive diagnosis.
The more specific chronic myeloid leukemias are
1. Chronic myelogenous leukemia, BCR-ABL1 positive (9875/3)
2. Atypical chronic myeloid leukemia, BCR-ABL1 negative (9876/3)
3. Chronic myelomonocytic leukemia (9945/3)
4. Juvenile myelomonocytic leukemia (9946/3)
If the characteristics of a specific subtype of chronic myeloid leukemia develop later in the course of the disease, change the histology code to the more specific diagnosis.
Treatment:
Chronic phase: Tyrosine kinase inhibitor. High-dose chemotherapy with donor stem cell transplant; BRM (interferon). OR Chemotherapy; splenectomy; clinical trial of lower-dose chemotherapy with donor stem cell transplant.
Accelerated phase: Donor stem cell transplant;; tyrosine kinase inhibitor; BRM, (interferon (with or without chemotherapy). Chemotherapy may be a single or multi-drug regimen.
Blast phase: Tyrosine kinase inhibitor; chemotherapy (single or multi-drug); bi=BRM (interferon); Donor stem cell transplant
The more specific chronic myeloid leukemias are
1. Chronic myelogenous leukemia, BCR-ABL1 positive (9875/3)
2. Atypical chronic myeloid leukemia, BCR-ABL1 negative (9876/3)
3. Chronic myelomonocytic leukemia (9945/3)
4. Juvenile myelomonocytic leukemia (9946/3)
If the characteristics of a specific subtype of chronic myeloid leukemia develop later in the course of the disease, change the histology code to the more specific diagnosis.
Treatment:
Chronic phase: Tyrosine kinase inhibitor. High-dose chemotherapy with donor stem cell transplant; BRM (interferon). OR Chemotherapy; splenectomy; clinical trial of lower-dose chemotherapy with donor stem cell transplant.
Accelerated phase: Donor stem cell transplant;; tyrosine kinase inhibitor; BRM, (interferon (with or without chemotherapy). Chemotherapy may be a single or multi-drug regimen.
Blast phase: Tyrosine kinase inhibitor; chemotherapy (single or multi-drug); bi=BRM (interferon); Donor stem cell transplant
Diagnostic Confirmation
This is a histology for which the Definitive Diagnostic Method does not include Genetics Data or Immunophenotyping, thus Diagnostic Confirmation should never be 3. If genetics and/or immunophenotyping are available, re-review to see if a more specific neoplasm can be coded.
Grade
Not Applicable
Module Rule
None
Alternate Names
Definition
No delineation of translocation, BCR-ABL1, or Phil chromosome noted to qualify for ICD-O-3 9863.
Specific term as defined by WHO, codes as 9875/3 and indicates the process has Ph+, BCR-ABL1 fusion and/or t(9;22)(q34;q11) demonstrated, as defined by ICD-O-3 for 9875 as well. Presumably myelogenous leukemia without genetic studies done would be coded to 9863.
Specific term as defined by WHO, codes as 9875/3 and indicates the process has Ph+, BCR-ABL1 fusion and/or t(9;22)(q34;q11) demonstrated, as defined by ICD-O-3 for 9875 as well. Presumably myelogenous leukemia without genetic studies done would be coded to 9863.
Definitive Diagnostic Methods
Bone marrow biopsy
Peripheral blood smear
Genetics Data
None
Immunophenotyping
None
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Immunotherapy
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-9 Codes
205.1 Chronic myeloid leukemia
208.1 Chronic leukemia of unspecified cell type
Corresponding ICD-10 Codes
C92.1 Chronic myeloid leukemia
C95.1 Chronic leukemia of unspecified cell type
Corresponding ICD-10-CM Codes (U.S. only)
C95.1 Chronic leukemia of unspecified cell type (effective October 01, 2015)
Signs and Symptoms
None
Diagnostic Exams
None
Progression and Transformation
None
Epidemiology and Mortality
None
Sources
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Chronic Myelogenous Leukemia (CML)
Pages: https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq
Section: General Information About Chronic Myelogenous Leukemia (CML)
Pages: https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq